#USA #New York #Gross Law Firm #Rocket Pharmaceuticals #RCKT

Important Notice for Rocket Pharmaceuticals Investors

Shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) are encouraged to reach out to The Gross Law Firm before the impending deadline of August 11, 2025. This notice aims to inform all shareholders who acquired shares during the specified class period, from February 27, 2025, to May 26, 2025, about their potential rights and avenues for recovery.

Background of the Case

According to reports, Rocket Pharmaceuticals purportedly made overly optimistic statements to investors, simultaneously withholding critical information regarding the safety and clinical trial protocols surrounding their product, RP-A501. These actions raised concerns when it was discovered that serious adverse events (SAEs) had occurred, including the unfortunate death of a participant enrolled in the clinical trial. Allegations claim that Rocket failed to disclose modifications made to the trial protocol, particularly the introduction of a novel immunomodulatory agent that may have influenced these adverse outcomes.

In a recent announcement on May 27, 2025, the FDA placed a hold on the Phase 2 pivotal study of RP-A501, following the SAE reports. It was revealed that management had decided to amend the trial protocol months prior but did not inform investors until the death occurred. The impact of this disclosure was immediate, with Rocket's stock experiencing a staggering decline of approximately 37% in just one trading day; prices plummeted from $6.27 per share to $2.33.

Why This Matters to Shareholders

For shareholders who purchased shares during the class period, understanding your rights and pursuing potential claims could be critical. The Gross Law Firm is ready to guide investors through this legal landscape. Participating in this class action could provide shareholders an opportunity to recover losses due to the alleged misleading actions of Rocket Pharmaceuticals.

Next Steps for Shareholders

If you have acquired shares of RCKT within the identified timeframe, it’s vital not to delay in taking action. Here's how to proceed:
1. Contact The Gross Law Firm using the provided link here.
2. Register your details to ensure you're kept informed throughout the case lifecycle. This service includes portfolio monitoring software that will send you updates on the case.
3. Keep in mind that while you do not need to be appointed as a lead plaintiff to participate, doing so will enhance your standing in the case.

If You Need Legal Assistance

The Gross Law Firm, noted for its expertise in class actions, is committed to upholding the rights of investors adversely affected by corporate wrongdoing. Their mission focuses on holding companies accountable for deceptive practices that lead to artificial inflation of stock prices. By retaining their services, you align yourself with a firm dedicated to achieving equitable outcomes for investors.

Contact Details

For further inquiries or assistance, you can reach The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

In conclusion, shareholders must act swiftly to protect their interests in Rocket Pharmaceuticals by contacting The Gross Law Firm before the deadline. This is not just an opportunity for recovery; it’s a stand for your rights as an investor.